Portal de Periódicos da CAPES

Serial Spot Hydroxyproline/Creatinine Ratios in Metastatic Prostatic Cancer

1983; Lippincott Williams & Wilkins; Volume: 129; Issue: 2 Linguagem: Inglês

10.1016/s0022-5347(17)52076-5

1527-3792

Stanley C. Hopkins, I. Nissenkorn, Genaro M. A. Palmieri, Melinda Ikard, Muhammad Moinuddin, Mark S. Soloway,

Hormonal and reproductive studies

No AccessJournal of Urology1 Feb 1983Serial Spot Hydroxyproline/Creatinine Ratios in Metastatic Prostatic Cancer S.C. Hopkins, I. Nissenkorn, G. M.A. Palmieri, M. Ikard, M. Moinuddin, and M.S. Soloway S.C. HopkinsS.C. Hopkins More articles by this author , I. NissenkornI. Nissenkorn Current address: Beilinson Medical Center, Petah Tiqva, Israel. More articles by this author , G. M.A. PalmieriG. M.A. Palmieri More articles by this author , M. IkardM. Ikard More articles by this author , M. MoinuddinM. Moinuddin More articles by this author , and M.S. SolowayM.S. Soloway More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)52076-5AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Analysis of urinary hydroxyproline levels offers a marker to monitor osseous involvement in patients with metastatic malignancies. Such a marker is needed in patients with prostatic cancer when bone metastases predominate. Thirty-two men with stage D2 prostatic cancer were monitored by bone scan, acid and alkaline phosphatase values, and urinary hydroxyproline, beginning from 4 to 36 months after initiation of hormonal manipulation and/or systemic chemotherapy. In patients with disease progression determined by bone scan serial urinary hydroxyproline values progressively increased and were significantly elevated compared to urinary values obtained from patients with a stable or improving scan (p <0.001). Simultaneous alkaline phosphatase determinations showed less significant differences between patient groups. Acid phosphatase did not reliably indicate osseous response to therapy. These data suggest that urinary hydroxyproline values are predictive as an early objective sign of osseous response in patients receiving therapy for stage D2 prostatic cancer. © 1983 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byO’Brien W and Lynch J (2018) Hydroxyproline as a Marker for Following Patients with Metastatic Prostate CancerJournal of Urology, VOL. 139, NO. 1, (66-68), Online publication date: 1-Jan-1988.Grayhack J (2018) Prostatic Carcinoma: ManagementJournal of Urology, VOL. 132, NO. 1, (92-92), Online publication date: 1-Jul-1984. Volume 129Issue 2February 1983Page: 319-323 Advertisement Copyright & Permissions© 1983 by The American Urological Association Education and Research, Inc.MetricsAuthor Information S.C. Hopkins More articles by this author I. Nissenkorn Current address: Beilinson Medical Center, Petah Tiqva, Israel. More articles by this author G. M.A. Palmieri More articles by this author M. Ikard More articles by this author M. Moinuddin More articles by this author M.S. Soloway More articles by this author Expand All Advertisement PDF downloadLoading ...